The King of Prussia company's CEO said the layoffs are necessary in an industry being reshaped by new technologies, ...
Importantly, it could work for all CF patients, whereas Vertex Pharmaceuticals' medicines target only those with certain ...
Zacks Investment Research on MSN
Vertex gears up to report Q1 earnings: What investors can expect
Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) earnings expected to grow: What to know ahead of next week's release
The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...
For decades, the 'shots on goal' model has driven up R&D costs while failing to deliver results. Vertex Pharmaceuticals just ...
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions ...
View Vertex, Inc. Class A VERX stock quote prices, financial information, real-time forecasts, and company news from CNN.
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $435.65, indicating a -1.37% shift from the previous trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results